In an­oth­er win for ri­val Aim­mune, FDA press­es pause on DB­V's peanut patch with ad­di­tion­al ques­tions

An­oth­er reg­u­la­to­ry set­back has strayed DBV Ther­a­peu­tics’s peanut al­ler­gy patch off the path to ap­proval.

On Mon­day, the com­pa­ny dis­closed that the FDA, which is …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER